Summary
Ensitrelvir is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Ensitrelvir to Long COVID: 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06161688, sponsored by Timothy Henrich). It plans or enrolled 40 participants. Registered activity dates to 2024. The literature layer holds 5 publications for this pair: 1 clinical trial publication and 4 other publications. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 15.0 (trials 4.0, literature 6.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 5 (4 other publications, 1 clinical trial publication) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Anti-inflammatory; Antiviral / Persistence |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06161688 | Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID Timothy Henrich · 2024 | active, not recruiting | Phase 2 | 40 |
Published literature
- Clinical trial publication (PubMed validation search) PubMed record PMID 38972603
- Review (PubMed validation search) PubMed record PMID 39444602
- Case series (PubMed validation search) PubMed record PMID 39552926
- Case report (PubMed validation search) PubMed record PMID 38333218
- Experimental study (PubMed validation search) PubMed record PMID 41066438
Mechanism and notes
Recorded mechanism or class: Anti-inflammatory; Antiviral / Persistence.
Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Ensitrelvir approved for Long COVID?
Ensitrelvir is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Ensitrelvir in clinical trials for Long COVID?
ClinicalTrials.gov lists 1 registered trial linking Ensitrelvir to Long COVID: 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06161688, sponsored by Timothy Henrich). It plans or enrolled 40 participants. Registered activity dates to 2024.
What does the evidence show for Ensitrelvir in Long COVID?
Trials of Ensitrelvir in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.